top of page
While Code Bio’s in-house development efforts are focused on building a pipeline of novel, urgently needed genetic medicines, Code Bio’s 3DNA platform has also demonstrated proof of concept in the delivery of multiple modalities with applicability to a broad range of diseases.
As a result, in addition to developing its own pipeline, Code Bio is engaged in partnership discussions with potential collaborators in the areas of gene therapy, siRNA, microRNA, ASOs, gene editing constructs, and small drug molecules.
At Code Bio, we believe collaboration is the foundation of discovery.
Contact us if you are interested in partnering.
bottom of page